Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Chronic Adolescent CDPPB Treatment Alters Short-Term, but not Long-Term, Glutamatergic Receptor Expression.

Lum JS, Millard SJ, Frank E, Matosin N, Huang XF, Ooi L, Newell KA.

Neurochem Res. 2018 Jun 23. doi: 10.1007/s11064-018-2584-x. [Epub ahead of print]

PMID:
29936568
2.

Understanding the Molecular Mechanisms Underpinning Gene by Environment Interactions in Psychiatric Disorders: The FKBP5 Model.

Matosin N, Halldorsdottir T, Binder EB.

Biol Psychiatry. 2018 May 15;83(10):821-830. doi: 10.1016/j.biopsych.2018.01.021. Epub 2018 Mar 21. Review.

PMID:
29573791
3.

Preclinical and Clinical Evidence of DNA Methylation Changes in Response to Trauma and Chronic Stress.

Matosin N, Cruceanu C, Binder EB.

Chronic Stress (Thousand Oaks). 2017 Feb 1;1. doi: 10.1177/2470547017710764. Epub 2017 Jun 16.

4.

Common variation in ZNF804A (rs1344706) is not associated with brain morphometry in schizophrenia or healthy participants.

Quidé Y, Matosin N, Atkins JR, Fitzsimmons C, Cairns MJ, Carr VJ; Australian Schizophrenia Research Bank (ASRB), Green MJ.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Mar 2;82:12-20. doi: 10.1016/j.pnpbp.2017.12.007. Epub 2017 Dec 13.

PMID:
29247760
5.

Stress-Related Memory Impairments Are Modulated by the Synergistic Action of Stress Hormones: Implications for PTSD.

Matosin N, Cruceanu C.

J Neurosci. 2017 Apr 19;37(16):4225-4227. doi: 10.1523/JNEUROSCI.3980-16.2017. No abstract available.

6.

Effects of common GRM5 genetic variants on cognition, hippocampal volume and mGluR5 protein levels in schizophrenia.

Matosin N, Newell KA, Quidé Y, Andrews JL, Teroganova N, Green MJ, Fernandez F.

Brain Imaging Behav. 2018 Apr;12(2):509-517. doi: 10.1007/s11682-017-9712-0.

PMID:
28405888
7.

Alterations of ubiquitin related proteins in the pathology and development of schizophrenia: Evidence from human and animal studies.

Andrews JL, Goodfellow FJ, Matosin N, Snelling MK, Newell KA, Huang XF, Fernandez-Enright F.

J Psychiatr Res. 2017 Jul;90:31-39. doi: 10.1016/j.jpsychires.2017.01.009. Epub 2017 Jan 18.

PMID:
28226265
8.

Neurodevelopmental Expression Profile of Dimeric and Monomeric Group 1 mGluRs: Relevance to Schizophrenia Pathogenesis and Treatment.

Lum JS, Fernandez F, Matosin N, Andrews JL, Huang XF, Ooi L, Newell KA.

Sci Rep. 2016 Oct 10;6:34391. doi: 10.1038/srep34391.

9.

Metabotropic Glutamate Receptor 5 as a Point of Convergence for Models of Obsessive-Compulsive Disorder and Autism Spectrum Disorder.

Matosin N, Siegel SJ.

Biol Psychiatry. 2016 Oct 1;80(7):504-6. doi: 10.1016/j.biopsych.2016.08.005. No abstract available.

PMID:
27601339
10.

Molecular evidence of synaptic pathology in the CA1 region in schizophrenia.

Matosin N, Fernandez-Enright F, Lum JS, Engel M, Andrews JL, Gassen NC, Wagner KV, Schmidt MV, Newell KA.

NPJ Schizophr. 2016 Jun 29;2:16022. doi: 10.1038/npjschz.2016.22. eCollection 2016.

11.

Erratum to: mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.

Engel M, Snikeris P, Matosin N, Newell KA, Huang XF, Frank E.

Psychopharmacology (Berl). 2016 Apr;233(8):1537. doi: 10.1007/s00213-016-4261-6. No abstract available.

PMID:
26955838
12.

mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.

Engel M, Snikeris P, Matosin N, Newell KA, Huang XF, Frank E.

Psychopharmacology (Berl). 2016 Apr;233(8):1349-59. doi: 10.1007/s00213-016-4230-0. Epub 2016 Feb 10. Erratum in: Psychopharmacology (Berl). 2016 Apr;233(8):1537.

PMID:
26861891
13.

Possibility of a sex-specific role for a genetic variant in FRMPD4 in schizophrenia, but not cognitive function.

Matosin N, Green MJ, Andrews JL, Newell KA, Fernandez-Enright F.

Neuroreport. 2016 Jan 6;27(1):33-8. doi: 10.1097/WNR.0000000000000491.

PMID:
26555035
14.

Shifting towards a model of mGluR5 dysregulation in schizophrenia: Consequences for future schizophrenia treatment.

Matosin N, Fernandez-Enright F, Lum JS, Newell KA.

Neuropharmacology. 2017 Mar 15;115:73-91. doi: 10.1016/j.neuropharm.2015.08.003. Epub 2015 Sep 6. Review.

PMID:
26349010
15.

Alterations of p75 neurotrophin receptor and Myelin transcription factor 1 in the hippocampus of perinatal phencyclidine treated rats.

Andrews JL, Newell KA, Matosin N, Huang XF, Fernandez-Enright F.

Prog Neuropsychopharmacol Biol Psychiatry. 2015 Dec 3;63:91-7. doi: 10.1016/j.pnpbp.2015.06.003. Epub 2015 Jun 10.

PMID:
26071990
16.

Metabotropic glutamate receptor 5, and its trafficking molecules Norbin and Tamalin, are increased in the CA1 hippocampal region of subjects with schizophrenia.

Matosin N, Fernandez-Enright F, Lum JS, Andrews JL, Engel M, Huang XF, Newell KA.

Schizophr Res. 2015 Aug;166(1-3):212-8. doi: 10.1016/j.schres.2015.05.001. Epub 2015 Jun 2.

PMID:
26048293
17.

Alterations of mGluR5 and its endogenous regulators Norbin, Tamalin and Preso1 in schizophrenia: towards a model of mGluR5 dysregulation.

Matosin N, Fernandez-Enright F, Fung SJ, Lum JS, Engel M, Andrews JL, Huang XF, Weickert CS, Newell KA.

Acta Neuropathol. 2015 Jul;130(1):119-29. doi: 10.1007/s00401-015-1411-6. Epub 2015 Mar 17.

PMID:
25778620
18.

Homer1/mGluR5 activity moderates vulnerability to chronic social stress.

Wagner KV, Hartmann J, Labermaier C, Häusl AS, Zhao G, Harbich D, Schmid B, Wang XD, Santarelli S, Kohl C, Gassen NC, Matosin N, Schieven M, Webhofer C, Turck CW, Lindemann L, Jaschke G, Wettstein JG, Rein T, Müller MB, Schmidt MV.

Neuropsychopharmacology. 2015 Mar 13;40(5):1222-33. doi: 10.1038/npp.2014.308.

20.

Negativity towards negative results: a discussion of the disconnect between scientific worth and scientific culture.

Matosin N, Frank E, Engel M, Lum JS, Newell KA.

Dis Model Mech. 2014 Feb;7(2):171-3. doi: 10.1242/dmm.015123.

21.
22.

Metabotropic glutamate receptor 5 binding and protein expression in schizophrenia and following antipsychotic drug treatment.

Matosin N, Frank E, Deng C, Huang XF, Newell KA.

Schizophr Res. 2013 May;146(1-3):170-6. doi: 10.1016/j.schres.2013.01.018. Epub 2013 Feb 23.

PMID:
23462049
23.

Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia.

Matosin N, Newell KA.

Neurosci Biobehav Rev. 2013 Mar;37(3):256-68. doi: 10.1016/j.neubiorev.2012.12.005. Epub 2012 Dec 17. Review.

PMID:
23253944

Supplemental Content

Loading ...
Support Center